Since GNBT is unable to bring "Complete Vaccine" to finish line at this very ripe time in the light of the recent mutant strain covid global outbreak, sell the patent and propriety rights to the vaccine to big pharma for enough money to launch other initiatives conditioned upon a 10-15% royalty on sales of the developed vaccine, or 1/3rd amount paid by any other company to develop or partner. Go on to other sustaining initiatives like health management. Company does not enough financing to run trials, and risk going bankrupt if drug not approved.
(1)
(1)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links